An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease

一种可注射植入物，提供长效药物输送，用于治疗慢性病

• 批准号: EP/S012265/1
• 负责人: Tom McDonald
• 金额: $ 119.8万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FS012265%2F1
• 关键词: Injectable; Implant; Providing; Long; Acting

Within Europe, chronic diseases are currently the leading cause of mortality and morbidity. In England alone, there are 15m people with long-term conditions who are estimated to account for 70% of the total health and social care spend. A significant factor in the management of chronic disease is the long-term nature of the treatment. Although often very efficient, therapies are only effective when combined with long-term medication adherence from the patient. Unfortunately, patient adherence is typically poor within long-term disease patient populations; only about 50% of patients adhere to their treatment regimes. Poor adherence can be addressed by the simplification of therapeutic regimes through reducing the dosing frequency. For example, when self-administered treatment regimens such as oral dosing are replaced with long acting formulations adherence can be greatly improved. Additionally, reducing the frequently of dosing is known to be appealing to patients with long-term therapy requirements. This proposal seeks to develop a new drug delivery system that could be easily injected into the body and would provide long-acting drug release. This technology would address issues caused by poor medication adherence. The drug delivery system would be composed of responsive polymer nanoparticles and drug nanoparticles that form a nanocomposite, entrapping a reservoir of drug upon injection into the body. After the drug has been released the materials would degrade into non-toxic components and leave the body. In order to accelerate the development of this novel technology toward clinical use, this project will consist of closely-integrated materials synthesis and biological assessment. The materials involved will be simultaneously prepared and evaluated in the presence of cells to check that they are biologically compatible. The responsive polymer nanoparticles will be synthesised to combine responsive behaviour with tuneable degradation, while the design of the drug nanoparticles will allow the drug release rate to be altered. A small number of optimised materials will undergo detailed biological evaluation. The resulting novel, biodegradable, nanocomposite material would have appropriate physical and biological properties for injection into the body. This technology will provide tuneable, long-acting release of drugs for the treatment of chronic disease.

在欧洲，慢性病目前是死亡和发病的主要原因。仅在英格兰，就有1500万人患有长期疾病，估计占医疗和社会保健总支出的70%。慢性病管理的一个重要因素是治疗的长期性。虽然通常非常有效，但只有在与患者的长期药物依从性相结合时，治疗才有效。不幸的是，在长期疾病患者人群中，患者依从性通常较差;只有约50%的患者依从其治疗方案。依从性差可通过减少给药频率简化治疗方案来解决。例如，当用长效制剂代替自我给药的治疗方案（例如口服给药）时，可以大大改善依从性。此外，已知降低给药频率对需要长期治疗的患者具有吸引力。这项提案旨在开发一种新的药物输送系统，可以很容易地注射到体内，并提供长效药物释放。这项技术将解决由于药物依从性差而引起的问题。药物递送系统将由响应性聚合物纳米颗粒和药物纳米颗粒组成，这些纳米颗粒形成纳米复合材料，在注射到体内时捕获药物的储存器。药物释放后，材料将降解为无毒成分并离开人体。为了加速这一新技术向临床应用的发展，该项目将包括紧密结合的材料合成和生物学评估。将在存在细胞的情况下同时制备和评价所涉及的材料，以检查其生物相容性。将合成响应性聚合物纳米颗粒以将联合收割机响应性行为与可调降解结合，而药物纳米颗粒的设计将允许改变药物释放速率。少量优化材料将进行详细的生物学评价。由此产生的新型的、可生物降解的纳米复合材料将具有适当的物理和生物学特性以用于注射到体内。这项技术将提供可调的、长效的药物释放，用于治疗慢性疾病。

项目成果

Redispersible nanosuspensions as a plausible oral delivery system for curcumin

可再分散纳米混悬剂作为姜黄素的合理口服给药系统

• DOI: 10.1016/j.foodhyd.2021.107005
• 发表时间: 2021
• 期刊: Food Hydrocolloids
• 影响因子: 10.7
• 作者: Elbaz N

Layer by layer self-assembly for coating a nanosuspension to modify drug release and stability for oral delivery

• DOI: 10.1016/j.foodhyd.2023.108908
• 发表时间: 2023-05
• 期刊: Food Hydrocolloids
• 影响因子: 10.7
• 作者: Nancy M. Elbaz;Lee M. Tatham;A. Owen;S. Rannard;Tom O. McDonald

Dual-responsive degradable core-shell nanogels with tuneable aggregation behaviour.

• DOI: 10.1039/d1ra07093b
• 发表时间: 2022-01-12
• 期刊: RSC advances
• 影响因子: 3.9
• 作者: Gray DM;Town AR;Niezabitowska E;Rannard SP;McDonald TO
• 通讯作者: McDonald TO

Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.

• DOI: 10.3390/v15112161
• 发表时间: 2023-10-27
• 期刊: Viruses
• 作者: Gallardo-Toledo E;Neary M;Sharp J;Herriott J;Kijak E;Bramwell C;Curley P;Arshad U;Pertinez H;Rajoli RKR;Valentijn A;Cox H;Tatham L;Kipar A;Stewart JP;Owen A
• 通讯作者: Owen A

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.

• DOI: 10.1002/cpt.2099
• 发表时间: 2021-07
• 期刊: Clinical pharmacology and therapeutics
• 影响因子: 6.7
• 作者: Boffito M;Back DJ;Flexner C;Sjö P;Blaschke TF;Horby PW;Cattaneo D;Acosta EP;Anderson P;Owen A
• 通讯作者: Owen A